China's biotech sector has transformed from industry outlier to innovation powerhouse, with Chinese assets now representing one-third of Big Pharma's global licensing deals. From Johnson & Johnson's pioneering BCMA CAR-T partnership to today's strategic alliances, industry leaders reveal how China became an essential source for next-generation therapeutics.